EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE. Preliminary Report of the Veterans Administration Cooperative Study

L. B. Seeff, E. C. Wright, J. D. Finkelstein, H. B. Greenlee, J. Hamilton, C. M. Leevy, C. H. Tamburro, Z. Vlahcevic, D. S. Zimmon, H. J. Zimmerman, B. F. Felsher, P. Garcia-Pont, A. A. Dietz, R. S. Koff, Thomas W Kiernan, E. R. Schiff, R. Zemel, N. Nath

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A randomised, double-blind, controlled trial has been undertaken to compare the efficacy of hepatitis B immune globulin (H.B.I.G.) with that of immune serum globulin (I.S.G.) for the prophylaxis of viral hepatitis. Participants in the trial were individuals exposed accidentally to material infectious for hepatitis (primarily viral B hepatitis). Preliminary evaluation of the first 302 of the 561 individuals entered into the study indicates that H.B.I.G. significantly reduced the frequencies of both clinical and sub-clinical hepatitis during the first 3-4 months after the injection. Less than 10% of H.B.I.G. recipients had detectable anti-HBs at the sixth month after the injection, suggesting that H.B.I.G. might need to be given every 3-4 months to continually exposed individuals. Further long-term evaluation is required in order to define more clearly those most likely to benefit from H.B.I.G..

Original languageEnglish (US)
Pages (from-to)939-941
Number of pages3
JournalThe Lancet
Volume306
Issue number7942
DOIs
StatePublished - Nov 15 1975
Externally publishedYes

Fingerprint

Serum Globulins
United States Department of Veterans Affairs
Hepatitis B
Immunoglobulins
Immune Sera
Hepatitis
Injections
Hepatitis A

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Seeff, L. B., Wright, E. C., Finkelstein, J. D., Greenlee, H. B., Hamilton, J., Leevy, C. M., ... Nath, N. (1975). EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE. Preliminary Report of the Veterans Administration Cooperative Study. The Lancet, 306(7942), 939-941. https://doi.org/10.1016/S0140-6736(75)90357-8

EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE. Preliminary Report of the Veterans Administration Cooperative Study. / Seeff, L. B.; Wright, E. C.; Finkelstein, J. D.; Greenlee, H. B.; Hamilton, J.; Leevy, C. M.; Tamburro, C. H.; Vlahcevic, Z.; Zimmon, D. S.; Zimmerman, H. J.; Felsher, B. F.; Garcia-Pont, P.; Dietz, A. A.; Koff, R. S.; Kiernan, Thomas W; Schiff, E. R.; Zemel, R.; Nath, N.

In: The Lancet, Vol. 306, No. 7942, 15.11.1975, p. 939-941.

Research output: Contribution to journalArticle

Seeff, LB, Wright, EC, Finkelstein, JD, Greenlee, HB, Hamilton, J, Leevy, CM, Tamburro, CH, Vlahcevic, Z, Zimmon, DS, Zimmerman, HJ, Felsher, BF, Garcia-Pont, P, Dietz, AA, Koff, RS, Kiernan, TW, Schiff, ER, Zemel, R & Nath, N 1975, 'EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE. Preliminary Report of the Veterans Administration Cooperative Study', The Lancet, vol. 306, no. 7942, pp. 939-941. https://doi.org/10.1016/S0140-6736(75)90357-8
Seeff, L. B. ; Wright, E. C. ; Finkelstein, J. D. ; Greenlee, H. B. ; Hamilton, J. ; Leevy, C. M. ; Tamburro, C. H. ; Vlahcevic, Z. ; Zimmon, D. S. ; Zimmerman, H. J. ; Felsher, B. F. ; Garcia-Pont, P. ; Dietz, A. A. ; Koff, R. S. ; Kiernan, Thomas W ; Schiff, E. R. ; Zemel, R. ; Nath, N. / EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE. Preliminary Report of the Veterans Administration Cooperative Study. In: The Lancet. 1975 ; Vol. 306, No. 7942. pp. 939-941.
@article{7839209b54214307bddd43d8185b967e,
title = "EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE. Preliminary Report of the Veterans Administration Cooperative Study",
abstract = "A randomised, double-blind, controlled trial has been undertaken to compare the efficacy of hepatitis B immune globulin (H.B.I.G.) with that of immune serum globulin (I.S.G.) for the prophylaxis of viral hepatitis. Participants in the trial were individuals exposed accidentally to material infectious for hepatitis (primarily viral B hepatitis). Preliminary evaluation of the first 302 of the 561 individuals entered into the study indicates that H.B.I.G. significantly reduced the frequencies of both clinical and sub-clinical hepatitis during the first 3-4 months after the injection. Less than 10{\%} of H.B.I.G. recipients had detectable anti-HBs at the sixth month after the injection, suggesting that H.B.I.G. might need to be given every 3-4 months to continually exposed individuals. Further long-term evaluation is required in order to define more clearly those most likely to benefit from H.B.I.G..",
author = "Seeff, {L. B.} and Wright, {E. C.} and Finkelstein, {J. D.} and Greenlee, {H. B.} and J. Hamilton and Leevy, {C. M.} and Tamburro, {C. H.} and Z. Vlahcevic and Zimmon, {D. S.} and Zimmerman, {H. J.} and Felsher, {B. F.} and P. Garcia-Pont and Dietz, {A. A.} and Koff, {R. S.} and Kiernan, {Thomas W} and Schiff, {E. R.} and R. Zemel and N. Nath",
year = "1975",
month = "11",
day = "15",
doi = "10.1016/S0140-6736(75)90357-8",
language = "English (US)",
volume = "306",
pages = "939--941",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7942",

}

TY - JOUR

T1 - EFFICACY OF HEPATITIS B IMMUNE SERUM GLOBULIN AFTER ACCIDENTAL EXPOSURE. Preliminary Report of the Veterans Administration Cooperative Study

AU - Seeff, L. B.

AU - Wright, E. C.

AU - Finkelstein, J. D.

AU - Greenlee, H. B.

AU - Hamilton, J.

AU - Leevy, C. M.

AU - Tamburro, C. H.

AU - Vlahcevic, Z.

AU - Zimmon, D. S.

AU - Zimmerman, H. J.

AU - Felsher, B. F.

AU - Garcia-Pont, P.

AU - Dietz, A. A.

AU - Koff, R. S.

AU - Kiernan, Thomas W

AU - Schiff, E. R.

AU - Zemel, R.

AU - Nath, N.

PY - 1975/11/15

Y1 - 1975/11/15

N2 - A randomised, double-blind, controlled trial has been undertaken to compare the efficacy of hepatitis B immune globulin (H.B.I.G.) with that of immune serum globulin (I.S.G.) for the prophylaxis of viral hepatitis. Participants in the trial were individuals exposed accidentally to material infectious for hepatitis (primarily viral B hepatitis). Preliminary evaluation of the first 302 of the 561 individuals entered into the study indicates that H.B.I.G. significantly reduced the frequencies of both clinical and sub-clinical hepatitis during the first 3-4 months after the injection. Less than 10% of H.B.I.G. recipients had detectable anti-HBs at the sixth month after the injection, suggesting that H.B.I.G. might need to be given every 3-4 months to continually exposed individuals. Further long-term evaluation is required in order to define more clearly those most likely to benefit from H.B.I.G..

AB - A randomised, double-blind, controlled trial has been undertaken to compare the efficacy of hepatitis B immune globulin (H.B.I.G.) with that of immune serum globulin (I.S.G.) for the prophylaxis of viral hepatitis. Participants in the trial were individuals exposed accidentally to material infectious for hepatitis (primarily viral B hepatitis). Preliminary evaluation of the first 302 of the 561 individuals entered into the study indicates that H.B.I.G. significantly reduced the frequencies of both clinical and sub-clinical hepatitis during the first 3-4 months after the injection. Less than 10% of H.B.I.G. recipients had detectable anti-HBs at the sixth month after the injection, suggesting that H.B.I.G. might need to be given every 3-4 months to continually exposed individuals. Further long-term evaluation is required in order to define more clearly those most likely to benefit from H.B.I.G..

UR - http://www.scopus.com/inward/record.url?scp=0016711363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016711363&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(75)90357-8

DO - 10.1016/S0140-6736(75)90357-8

M3 - Article

C2 - 53428

AN - SCOPUS:0016711363

VL - 306

SP - 939

EP - 941

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7942

ER -